Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-pkrb
- Development stage
- Approved
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab-pkrb is a biosimilar monoclonal antibody of trastuzumab, marketed under the brand name **Herzuma**. It is a humanized IgG1 kappa monoclonal antibody that targets the extracellular domain of the **HER2/erbB2 (human epidermal growth factor receptor 2)**, which is overexpressed in certain cancers, most notably some forms of breast cancer. By binding to HER2, trastuzumab-pkrb inhibits downstream signaling pathways related to cell proliferation and survival, mediates **antibody-dependent cellular cytotoxicity (ADCC)**, and helps destroy HER2-overexpressing tumor cells. It is indicated for the treatment of HER2-overexpressing breast cancer and administered by intravenous infusion. Trastuzumab-pkrb was developed as a biosimilar to trastuzumab (Herceptin) and is approved for use as an adjuvant and in metastatic breast cancer settings, either alone or alongside other chemotherapy agents.
- Brand names
- Herzuma
- Other names
- Herzuma
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab-pkrb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab-pkrb.